Upregulation of endogenous p53 and induction of in vivo apoptosis in B-lineage lymphomas of Eμ-myc transgenic mice by deregulated c-myc transgene

Molecular Carcinogenesis

Volumn 18, Issue 2, 1997, Pages 66-77

  Prasad, V S ^a   LaFond, Richard E ^b   Zhou, Ming ^a   Jacobsen, Karen A ^c   Osmond, Dennis G ^c   Sidman, Charles L ^a,d  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d 3110 MSB ^*  (United States)

Author keywords

Apoptosis; c myc; E myc transgenic mice; p53

Indexed keywords

PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TRANSGENIC MOUSE;

EID: 0030893175     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199702)18:2<66::AID-MC2>3.0.CO;2-O     Document Type: Article

References (72)

1. DePinho RA, Schreiber AN, Alt FW. myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 57:1-46, 1991.
2. Persson H, Leder P. Nuclear localization and DNA binding properties of a protein expressed by human c-myc oncogene. Science 225:718-721, 1984.
3. Kretzner L, Blackwood EM, Eisenman RN. Myc and Max proteins possess distinct transcriptional activities. Nature 359:426-429, 1992.
4. Kelly K, Siebenlist U. The regulation and expression of c-myc in normal and malignant cells. Annu Rev Immunol 4:317-338, 1986.
5. Gerondakis S, Cory S, Adams JM. Translocation of the myc cellular oncogene to the immunoglobulin heavy chain locus in murine plasmacytomas is an imprecise reciprocal exchange. Cell 36:973-982, 1984.
6. Erikson J, ar Rushdi A, Drwinga HL, Nowell PC, Croce CM. Transcriptional activation of the translocated c-myc oncogene in Burkitt's lymphoma. Proc Natl Acad Sci USA 80:820-824, 1983.
7. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533-538, 1985.
8. Sidman CL, Shaffer DJ, Jacobsen K, Vargas SR, Osmond DG. Cell populations during tumorigenesis in Eμ-myc transgenic mice. Leukemia 7:887-895, 1993.
9. Adams JM, Cory S. Transgenic models of tumor development. Science 254:1161-1167, 1991.
10. Prasad VS, Temple MJ, Denial TM, et al. Heterogeneity of B-lymphoid tumors in Eμ-myc transgenic mice. Cytometry 23:131-139, 1995.
11. Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice. Cell 47:11-18, 1986.
12. Sidman CL, Denial TM, Marshall JD, Roths JB. Multiple mechanisms of tumorigenesis in Eμ-myc transgenic mice. Cancer Res 53:1665-1669, 1993.
13. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The Eμ-myc transgenic mouse: A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 167:353-371, 1988.
14. Schmidt EV, Pattengale PK, Weir L, Leder P. Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: A pre-B-cell lymphoma model. Proc Natl Acad Sci USA 85:6047-6051, 1988.
15. Adams JM, Cory S. Oncogene co-operation in leukaemogenesis. Cancer Surv 15:119-141, 1992.
16. Alexander WS, Bernard O, Cory S, Adams JM. Lymphomagenesis in Eμ-myc transgenic mice can involve ras mutations. Oncogene 4:575-581, 1989.
17. Alexander WS, Adams JM, Cory S. Oncogene cooperation in lymphocyte transformation: Malignant conversion of Eμ-myc transgenic pre-B cells in vitro is enhanced by v-Ha-ras or v-raf but not v-abl. Mol Cell Biol 9:67-73, 1989.
18. Langdon WY, Harris AW, Cory S. Acceleration of B-lymphoid tumorigenesis in Eμ-myc transgenic mice by v-H-ras and v-raf but not v-abl. Oncogene Res 4:253-258, 1989.
19. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging. Cell 65:737-752, 1991.
20. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:255-256, 1980.
21. Martin SJ, Green DR, Cotter TG. Dicing with death: Dissecting the components of the apoptosis machinery. Trends Biochem Sci 19:26-30, 1994.
22. Bursch W, Paffe S, Putz B, Barthel G, Schulte HR. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. Carcinogenesis 11:847-853, 1990.
23. Schwartz LM. The role of cell death genes during development. Bioessays 13:389-395, 1991.
24. Williams GT. Programmed cell death: Apoptosis and oncogenesis. Cell 65:1097-1098, 1991.
25. Raff MC. Social controls on cell survival and cell death. Nature 356:397-400, 1992.
26. White E. Death-defying acts: A meeting review on apoptosis. Genes Dev 7:2277-2284, 1993.
27. Bissonnette RP, Shi Y, Mahboubi A, Glynn JM, Green DR. c-myc and apoptosis. In: Tomei LD, Cope FO (eds), Current Communications in Cell and Molecular Biology: Apoptosis II: The Molecular Basis of Apoptosis in Disease, Vol 8. Cold Spring Harbor Laboratory Press, New York, 1994, pp. 327-356.
28. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915-1922, 1991.
29. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128, 1992.
30. Shi Y, Glynn JM, Guilbert U, Cotter TG, Bissonnette RP, Green DR. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257:212-214, 1992.
31. Bissonnette RP, Echeverri R, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359:552-554, 1992.
32. Milner AE, Grand RJA, Waters CM, Gregory CD. Apoptosis in Burkitt lymphoma cells is driven by c-myc. Oncogene 8:3385-3391, 1993.
33. Hermeking H, Eick D. Mediation of c-myc-induced apoptosis by p53. Science 265:2091-2093, 1994.
34. Wagner AJ, Kokontis JM, Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev 8:2817-2830, 1994.
35. Berard CW. Morphological definition of Burkitt's tumour: Historical review and present status. IARC Sci Publ 60:31-35, 1985.
36. Sarraf CE, Bowen ID. Kinetic studies on a murine sarcoma and an analysis of apoptosis. Br J Cancer 54:989-998, 1986.
37. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide ranging implication in tissue kinetics. Br J Cancer 26:239-257, 1972.
38. Kerr JFR, Searle J. A suggested explanation for the paradoxically slow growth rate of basal-cell carcinomas that contain numerous mitotic figures. J Pathol 107:41-44, 1972.
39. Jacobsen KA, Prasad VS, Sidman CL, Osmond DG. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of Eμ-myc transgenic mice. Blood 84:2784-2794, 1994.
40. Taylor BA, Rowe L. Genes for serum amyloid A proteins map to chromosome 7 in the mouse. Mol Gen Genet 195:491-499, 1984.
41. Prasad VS, Sidman CL. Cell cycle analysis and DNA aneuploidy in autoimmune mice homozygous for the lpr and gld mutations. J Immunol 147:4200-4206, 1991.
42. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279, 1991.
43. Evan GI, Lewis GK, Ramsay G, Bishop JM. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 5:3610-3616, 1985.
44. LaFond RE, Eaton RB, Watt RA, Villee CA, Actor JK, Schur PH. Autoantibodies to c-myc protein: Elevated levels in patients with African Burkitt's lymphoma and normal Ghanians. Autoimmunity 13:215-224, 1992.
45. Hann SR, Eisenman RN. Two proteins encoded by the human c-myc oncogene: Differential expression in neoplasia. Mol Cell Biol 4:2486-2497, 1984.
46. Fung KM, Messing A, Lee VM, Trojanowski JQ. A novel modification of the avidin-biotin complex method for immunohistochemical studies of transgenic mice with murine monoclonal antibodies. J Histochem Cytochem 40:1319-1328, 1992.
47. Allen RD, StaleyTA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versus-host-disease. Eur J Immunol 23:333-337, 1993.
48. Sulston JE, Horvitz HR. Post-embryonic cell lineages of the nematode Caenorhabditis elegans. Dev Biol 56:110-156, 1977.
49. Dipasquale B, Youle RJ. Programmed cell death in heterokaryons: A study of the transfer of apoptosis between nuclei. Am J Pathol 141:1471-1479, 1992.
50. Sidman CL, Marshall JD, Harris AW. Genetic studies on Eμ-myc transgenic mice. Curr Top Microbiol Immunol 141:94-99, 1988.
51. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915, 1990.
52. Mercer WE, Shields MT, Amin M, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87:6166-6170, 1990.
53. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985.
54. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442, 1988.
55. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241-251, 1993.
56. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243, 1991.
57. Rustgi AK. Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product. Nature 352:541-544, 1991.
58. van Ewijk W, van Soest PL, van den Engh GJ. Fluorescence analysis and anatomic distribution of mouse T lymphocyte subsets defined by monoclonal antibodies to the antigens Thy-1, Lyt-1, Lyt-2, and T-200. J Immunol 127:2594-2604, 1981.
59. Guidry AJ, Srikumaran S, Goldsby RA. Production and characterization of bovine immunoglobulins from bovine X murine hybridomas. Methods Enzymol 121:244-265, 1986.
60. Palmiter RD, Brinster RL. Transgenic mice. Cell 41:343-345, 1985.
61. Wang Y, Ramqvist T, Szekely L, Axelson H, Klein G, Wiman KG. Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. Cell Growth Differ 4:467-473, 1993.
62. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 351:453-456, 1991.
63. Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 84:2391-2411, 1994.
64. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 353:345-347, 1991.
65. Reisman D, Elkind NB, Roy B, Beamon J, Rotter V. c-Myc transactivates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 4:57-65, 1993.
66. Hsu B, Martin MC, El-Naggar AK, Stephens LC, Brisbay S, McDonnell TJ. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene 11:175-179, 1995.
67. Oren M. The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev 11:141-148, 1992.
68. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689-1694, 1984.
69. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
70. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes [see comments]. Nature 362:847-849, 1993.
71. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329-339, 1994.
72. Alexander WS, Schrader JW, Adams JM. Expression of the c-myc oncogene under control of an immunoglobulin enhancer in Eμ-myc transgenic mice. Mol Cell Biol 7:1436-1444, 1987.